Clinical trials
Completed Phase 1 trials in Singapore
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
280 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 5 |
| 2007 | 8 |
| 2008 | 9 |
| 2009 | 28 |
| 2010 | 29 |
| 2011 | 31 |
| 2012 | 26 |
| 2013 | 18 |
| 2014 | 13 |
| 2015 | 17 |
| 2016 | 12 |
| 2017 | 12 |
| 2018 | 12 |
| 2019 | 9 |
| 2020 | 9 |
| 2021 | 10 |
| 2022 | 14 |
| 2023 | 6 |
| 2024 | 2 |
| 2025 | 7 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 280 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 81 |
| Pfizer | 55 |
| Novartis Pharmaceuticals | 23 |
| Bayer | 11 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 11 |
| Hoffmann-La Roche | 10 |
| National University Hospital, Singapore | 9 |
| National Cancer Centre, Singapore | 8 |
| Singapore National Eye Centre | 6 |
| ASLAN Pharmaceuticals | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 18 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Neoplasms | 12 |
| Hepatitis B, Chronic | 9 |
| Carcinoma, Hepatocellular | 8 |
| Breast Neoplasms | 6 |
| Arthritis, Rheumatoid | 5 |
| Carcinoma, Renal Cell | 5 |
| Hepatitis B | 5 |
| Liver Neoplasms | 5 |
Trials
Showing 1 to 25 of 280. Each trial links to its page on Pharma Observatory.
180 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.